Siemens and Alibaba Cloud signed a strategic cooperation agreement, in which both parties will leverage their technological advantages in their respective fields to jointly promote the integration of cloud computing, AI big models and industry, enabling Chinese enterprises to improve innovation and productivity, and injecting acceleration into the high-quality development of China's economy.

Today, in collaboration with single cell genomics company, Honeycomb Biotechnologies (“Honeycomb”), Revvity (NYSE: RVTY) announced the launch of a suite of new solutions and services that expand the frontiers of single cell biology: the HIVE™ CLX Single-Cell RNAseq Solution, BeeNetPLUS analysis workflow, and for single cell researchers based in the United States, a new HIVE CLX Service offering.

Based on the advantages of their respective fields, the two companies will carry out in-depth cooperation in life information and support, in vitro diagnosis, medical imaging, overall solutions for two cancer screening, hospital department equipment, information construction, etc., and jointly establish the "Hybribio-Mindray Standardized Laboratory" to achieve complementary advantages and resource sharing.

MOROCCO – Techniques Science Santé (T2S), a distributor of high-tech medical equipment based in Casablanca, has expanded a multi-year agreement with American company GE Healthcare, with a focus on ultra-modern modern technology.

Prenetics Global Limited, a leading genomics-driven health sciences company, and Prof. Dennis Lo today announce they have entered into an agreement to establish a joint venture named Insighta. The board of directors of Prenetics Global Limited has unanimously approved the transaction.

Oxford Nanopore Technologies (Oxford Nanopore) and leading China-based diagnostic companies, Zheijiang Digena Diagnostic Technology Co. Ltd (Digena) and Wuhan Dgensee Clinical Laboratory Co., Ltd (Dgensee), today announced a series of strategic collaborations that aim to bring nanopore sequencing technology and instruments to the clinical market in China.

Recently, Genalive, a joint venture between BGI Almanahil Health for Medical Services (a wholly owned subsidiary of BGI Genomics) and Tibbiyah Holding (a wholly owned subsidiary of Saudi Al Faisaliah Group), opened its independent clinical laboratory.

Breast Cancer Canada said on Thursday that it has launched a new grant program in collaboration with AstraZeneca Canada and Illumina.

Eli Lilly and Verve Therapeutics on Thursday said they have entered into an exclusive research collaboration to advance a preclinical gene-editing therapy for atherosclerotic cardiovascular disease (ASCVD) into the clinical stage.

MGI Tech, a Shenzhen, China-based firm focused on the development and distribution of sequencing instruments and reagents, on Wednesday announced that it has signed a licensing agreement with Xpress Genomics.